Name
Eribulin
Alternate Names
B1939
E7389
ER-086526
eribulin mesylate
Halaven
Abbreviations
None
Category
Chemotherapy
Subcategory
Inhibitor of microtubular dynamics
NSC Number
NSC707389
Primary Site
Histology
None
Remarks
Eribulin mesylate was approved by the US FDA on November 15, 2010, to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease, including both anthracycline and taxane-based chemotherapies.
January 28, 2016: FDA approved Halaven (eribulin) for the treatment of liposarcoma that cannot be removed by surgery (unresectable) or is advanced/metastatic. this treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.
January 28, 2016: FDA approved Halaven (eribulin) for the treatment of liposarcoma that cannot be removed by surgery (unresectable) or is advanced/metastatic. this treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.
Coding
This drug should be coded